Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Dermira jumps on Phase IIb atopic dermatitis readout

Brian Moy, Assistant Editor
March 18, 2019 5:37 PM UTC

Dermira added $5.77 (84%) to $12.61 on Monday after reporting that all three doses of lebrikizumab met the primary endpoint in a Phase IIb trial to treat adults with moderate-to-severe atopic dermatitis. Dermira Inc. (NASDAQ:DERM) plans to start a Phase III program of the anti-IL-13 mAb by year end.

After market close Monday, Dermira proposed to raise $110 million in a follow-on underwritten by Citigroup, Cowen, Cantor Fitzgerald, Guggenheim Securities, Needham and H.C. Wainwright...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Dermira Inc.

Genentech Inc.

BCIQ Target Profiles

Interleukin-13 (IL-13)